The global market for Fluorescence Guided Surgery Systems was estimated at US$208.6 Million in 2024 and is projected to reach US$454.9 Million by 2030, growing at a CAGR of 13.9% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Fluorescence Guided Surgery Systems market.
Segments: Type (SPY Systems, PDE Systems, VS3 Iridium Systems, Other Types); Surgery (Open Surgery, Laparoscopy/Endoscopy Surgery); Application (Cancer Surgery Application, Cardiovascular Surgery Application, Other Applications)
Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.
The analysts continuously track trade developments worldwide, drawing insights from leading global economists and over 200 industry and policy institutions, including think tanks, trade organizations, and national economic advisory bodies. This intelligence is integrated into forecasting models to provide timely, data-driven analysis of emerging risks and opportunities.
Global Fluorescence Guided Surgery Systems Market - Key Trends & Drivers Summarized
Why Is Fluorescence Guided Surgery Becoming a Game-Changer in Oncology and Neurosurgery?
Fluorescence guided surgery (FGS) is revolutionizing surgical precision by enabling real-time visualization of tumors, lymph nodes, and critical tissues using fluorescent dyes. This technique is particularly valuable in oncology, neurosurgery, and minimally invasive procedures, where precise tumor margin detection is essential for complete resection. The growing adoption of personalized cancer treatment and the increasing prevalence of solid tumors are driving demand for FGS systems. Additionally, advancements in near-infrared (NIR) imaging and targeted fluorescence contrast agents are enhancing surgical accuracy, reducing recurrence rates, and improving patient survival. As precision medicine gains traction, fluorescence guided surgery is becoming a standard in complex surgical interventions.What Technological Advancements Are Improving Fluorescence Guided Surgery Systems?
Breakthroughs in molecular imaging, AI-powered fluorescence mapping, and biocompatible contrast agents are enhancing the efficacy of FGS systems. The development of targeted fluorescent probes that bind selectively to cancerous tissues is improving tumor visibility and reducing damage to healthy structures. AI-driven imaging software is enabling real-time tissue differentiation, guiding surgeons more effectively during procedures. Additionally, hybrid imaging systems combining fluorescence with other imaging modalities, such as MRI and PET scans, are providing multi-layered insights for better surgical decision-making. The integration of robotic-assisted fluorescence guided surgery is further enhancing precision and reducing invasiveness in complex operations.How Are Regulations and Market Trends Influencing Fluorescence Guided Surgery?
Regulatory agencies such as the FDA and EMA oversee the approval of fluorescence contrast agents and imaging systems, ensuring their safety and effectiveness. The increasing emphasis on intraoperative imaging and precision oncology is driving the adoption of FGS in cancer treatment protocols. Additionally, the demand for minimally invasive procedures is encouraging hospitals to invest in advanced fluorescence-guided laparoscopic and robotic surgery systems. The expansion of AI-assisted surgical planning tools is also influencing market growth, enabling better preoperative mapping of tumors and vascular structures. As surgical technology evolves, fluorescence guided surgery is becoming an indispensable tool for improving patient outcomes.What’s Driving the Future Growth of the Fluorescence Guided Surgery Systems Market?
The future of FGS is being shaped by AI-enhanced imaging analytics, next-generation fluorescent contrast agents, and the increasing adoption of robotic-assisted surgical platforms. The development of targeted molecular imaging dyes for specific cancers will further improve tumor localization and surgical precision. AI-powered decision support tools will enhance real-time intraoperative guidance, reducing surgical errors and improving resection completeness. Additionally, the expansion of tele-surgical and remote robotic surgery applications will make FGS more accessible in underserved regions. As demand for precision surgery grows, fluorescence guided surgery will continue to redefine modern surgical oncology and neurosurgery.Report Scope
The report analyzes the Fluorescence Guided Surgery Systems market, presented in terms of market value (US$ Thousand). The analysis covers the key segments and geographic regions outlined below.Segments: Type (SPY Systems, PDE Systems, VS3 Iridium Systems, Other Types); Surgery (Open Surgery, Laparoscopy/Endoscopy Surgery); Application (Cancer Surgery Application, Cardiovascular Surgery Application, Other Applications)
Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.
Key Insights:
- Market Growth: Understand the significant growth trajectory of the SPY Systems segment, which is expected to reach US$209.7 Million by 2030 with a CAGR of a 13.0%. The PDE Systems segment is also set to grow at 13.3% CAGR over the analysis period.
- Regional Analysis: Gain insights into the U.S. market, estimated at $56.8 Million in 2024, and China, forecasted to grow at an impressive 18.4% CAGR to reach $96.3 Million by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.
Why You Should Buy This Report:
- Detailed Market Analysis: Access a thorough analysis of the Global Fluorescence Guided Surgery Systems Market, covering all major geographic regions and market segments.
- Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
- Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Fluorescence Guided Surgery Systems Market.
- Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.
Key Questions Answered:
- How is the Global Fluorescence Guided Surgery Systems Market expected to evolve by 2030?
- What are the main drivers and restraints affecting the market?
- Which market segments will grow the most over the forecast period?
- How will market shares for different regions and segments change by 2030?
- Who are the leading players in the market, and what are their prospects?
Report Features:
- Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
- In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
- Company Profiles: Coverage of players such as Accuray Incorporated, Arthrex, Inc., Bracco Imaging S.p.A., Curadel LLC, Elekta AB and more.
- Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.
Select Competitors (Total 37 Featured):
- Accuray Incorporated
- Arthrex, Inc.
- Bracco Imaging S.p.A.
- Curadel LLC
- Elekta AB
- Fluoptics
- Getinge AB
- Hamamatsu Photonics K.K.
- Intuitive Surgical, Inc.
- Karl Kaps GmbH & Co. KG
- Karl Storz SE & Co. KG
- Leica Microsystems (Danaher Corporation)
- LI-COR Biosciences
- Lumicell Inc.
- Medtronic plc
- Mizuho Medical Co., Ltd.
- MolecuLight Inc.
- NICO Corporation
- Novadaq Technologies Inc. (Stryker)
- Olympus Corporation
Tariff Impact Analysis: Key Insights for 2025
Global tariff negotiations across 180+ countries are reshaping supply chains, costs, and competitiveness. This report reflects the latest developments as of April 2025 and incorporates forward-looking insights into the market outlook.The analysts continuously track trade developments worldwide, drawing insights from leading global economists and over 200 industry and policy institutions, including think tanks, trade organizations, and national economic advisory bodies. This intelligence is integrated into forecasting models to provide timely, data-driven analysis of emerging risks and opportunities.
What’s Included in This Edition:
- Tariff-adjusted market forecasts by region and segment
- Analysis of cost and supply chain implications by sourcing and trade exposure
- Strategic insights into geographic shifts
Buyers receive a free July 2025 update with:
- Finalized tariff impacts and new trade agreement effects
- Updated projections reflecting global sourcing and cost shifts
- Expanded country-specific coverage across the industry
Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERSIV. COMPETITION
1. MARKET OVERVIEW
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
III. MARKET ANALYSIS
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Accuray Incorporated
- Arthrex, Inc.
- Bracco Imaging S.p.A.
- Curadel LLC
- Elekta AB
- Fluoptics
- Getinge AB
- Hamamatsu Photonics K.K.
- Intuitive Surgical, Inc.
- Karl Kaps GmbH & Co. KG
- Karl Storz SE & Co. KG
- Leica Microsystems (Danaher Corporation)
- LI-COR Biosciences
- Lumicell Inc.
- Medtronic plc
- Mizuho Medical Co., Ltd.
- MolecuLight Inc.
- NICO Corporation
- Novadaq Technologies Inc. (Stryker)
- Olympus Corporation
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 370 |
| Published | April 2025 |
| Forecast Period | 2024 - 2030 |
| Estimated Market Value ( USD | $ 208.6 Million |
| Forecasted Market Value ( USD | $ 454.9 Million |
| Compound Annual Growth Rate | 13.9% |
| Regions Covered | Global |
